Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,701.00
Ask: 1,701.50
Change: 32.00 (1.91%)
Spread: 0.50 (0.029%)
Open: 1,685.50
High: 1,718.50
Low: 1,673.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Big Pharma's bet on Big Data creates opportunities and risks

Tue, 26th Jan 2016 13:07

* Novartis plans to sell cloud-connected inhaler by 2019

* Part of companies' push into "Medical Internet of Things"

* Pharma and tech firms teaming up in hunt for Big Data

* But web-enabled devices present privacy and security risks

By John Miller

ZURICH, Jan 26 (Reuters) - Novartis wants everypuff of its emphysema drug Onbrez to go into the cloud.

The Swiss drugmaker has teamed up with U.S. technology firmQualcomm to develop an internet-connected inhaler thatcan send information about how often it is used to remotecomputer servers known as the cloud.

This kind of new medical technology is designed to allowpatients to keep track of their drug usage on their smartphonesor tablets and for their doctors to instantly access the dataover the web to monitor their condition.

It also creates a host of "Big Data" opportunities for thecompanies involved - with huge amounts of information about amedical condition and the efficacy of a drug or device beingwirelessly transmitted to a database from potentially thousands,even millions, of patients.

The potential scale of the so-called "Medical Internet ofThings" has not been lost on pharmaceutical and tech firmsaround the world, both big companies hunting growth and smallerones looking to provide bespoke products and services.

It has created unlikely alliances.

Novartis' domestic rival Roche has also teamed upwith Qualcomm and Danish diabetes drugmaker Novo Nordisk has partnered with IBM on cloud-linked deviceprojects, for example, while healthcare device maker Medtronic is working with a U.S. data-analytics firm Glooko.

GlaxoSmithKline, meanwhile, is in talks withQualcomm about a medical technology joint venture potentiallyworth up to $1 billion, according to people familiar with thematter.

However, with the opportunity comes risk.

Security experts warn that hacked medical information can beworth more than credit card details on the black market asfraudsters can use it to fake IDs to buy medical equipment ordrugs that can be resold, or file bogus insurance claims.

The U.S. Centers for Disease Control and Preventionestimates there are 35 million U.S. hospital discharges a year,a billion doctor and hospital visits and even moreprescriptions, much of which is stored in cloud databases.

CLOUD CONCERN

Now the "Medical Internet of Things" is introducing more andmore web-connected devices into the equation and pushing evenmore confidential patient data on to the cloud.

This is creating potential new opportunities for thievesseeking to penetrate medical companies' security where they maytarget names, birth dates, policy numbers, billing data and thediagnosis codes needed to obtain drugs, say experts.

"The weakest link tends to be the medical device itself,"said Rick Valencia, senior vice president of Qualcomm Life,Qualcomm's four-year-old healthcare unit. "They weren't designedwith the idea in mind that they would be going over the networkand the information would be residing in cloud infrastructure."

Medtronic, the world's largest standalone medical devicemaker, said in 2014 it lost patient records in separatecyberattacks at its diabetes business.

"The more information, the easier identity theft is and themore valuable the profiles that the hacker can sell to thirdparties," said Erik Vollebregt, a lawyer in Amsterdam whospecialises in medical device cybersecurity and privacy.

He said it could also be possible for criminals to hack intoweb-connected medical devices, and threaten the lives ofpatients, to blackmail the manufacturer.

Despite no documented patient-endangering hacks, the U.S.Food and Drug Administration warned last year an infusion pumpcould be vulnerable to attack and asked healthcare providers tostop using it.

SMART LENS

Novartis aims to have its inhaler for chronic lung disease,to be on the market by 2019. Other pharma-tech alliances includeAerocrine and Microsoft, which are workingtogether on a cloud project to analyse data from allergy andasthma patients.

Google is, meanwhile, working with Frenchdrugmaker Sanofi to collect and analyse informationfrom diabetes sufferers. The U.S. tech giant alsohas a partnership with Novartis to develop a smart contact lensthat can monitor diabetics' glucose levels.

All the companies involved in such projects say they aregoing to extreme lengths to protect patients' data from hackers.

Philips has turned to San Francisco-basedidentity-management software maker ForgeRock to keep data fromthe Dutch company's medical devices from falling into the wronghands.

Software security expert Marie Moe, of Norway's SINTEFscientific research foundation, said the wireless ports in thepacemaker that keeps her heart beating left it vulnerable tointrusion - but that she could not survive without the device.

"Wireless interfaces are a great benefit to certain patientgroups," she told Reuters. "But as a security researcher, I knowconnectivity also means vulnerability." (Additional reporting by Julie Steenhuysen in Chicago, JimFinkle in Boston and Ben Hirschler in London; Editing by PravinChar)

More News
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more
20 Feb 2024 15:10

PRESS: AJ Bell founder to join Applied Nutrition ahead of IPO - Sky

(Alliance News) - Supplements maker Applied Nutrition, plotting a London stock market float, is to add AJ Bell PLC founder Andy Bell as its chair, Sky News reported on Tuesday.

Read more
20 Feb 2024 08:55

IN BRIEF: Diageo welcomes GSK's CFO as non-executive director

Diageo PLC - London-based brewer and distiller sells more than 200 drinks brands, including Guinness stout, Captain Morgan rum and Johnnie Walker whisky - Appoints GSK PLC's chief financial officer and executive director, Julie Brown, as a non-executive director. Says she will succeed Alan Stewart as chair of the audit committee after his retirement following the firm's annual general meeting in September. Chair Javier Ferran says: "Julie brings many years of experience in financial, commercial and strategic roles in international companies operating in highly regulated industries. She is strongly committed to enabling diversity in business and to creating sustainable, long-term value for stakeholders. I look forward to her contribution to Board discussions and to working with her in progressing Diageo's ambition to be one of the most trusted and respected consumer products companies in the world."

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.